Laureate Pharma Announces Agreement with Enobia Pharma, Inc.
- Category: Proteins and Peptides
- Published on Wednesday, 01 August 2007 04:00
- Hits: 1773
Princeton, NJ, USA | July 31, 2007| Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Enobia Pharma, a biotechnology company actively engaged in the development of enzyme replacement therapy for the treatment of hypophosphatasia. According to the agreement Laureate will produce Enobia Pharma's fusion protein for treatment of hypophosphatasia, a rare, and sometimes fatal metabolic bone disease characterized by skeletal hypomineralization. Terms of the manufacturing agreement were not disclosed.
"We are delighted by the confidence Enobia has shown by continuing to utilize our specialized experience in the manufacture of fusion proteins," said Robert J. Broeze, President & CEO of Laureate. "We have a successful relationship with Enobia and will work with them closely to help them achieve their manufacturing objectives."
"Our partnership with Laureate is an important component of our manufacturing strategy. We look forward to our partnership with Laureate and advancing our hypophosphatasia program into the clinic," said Robert Heft, President and CEO of Enobia.
About Laureate Pharma, Inc.
About Enobia Pharma, Inc
Enobia Pharma is a privately held Canadian biotech company founded in 1997. The Company is engaged primarily in the discovery and clinical development of therapeutics to treat bone diseases where no drug therapy exists. Enobia anticipates initiating clinical studies in its lead program, enzyme-replacement therapy for hypophosphatasia, in the summer of 2008. The head office of Enobia is located at 2901 Rachel Street East, Suite 23, in Montreal, Quebec, CANADA. For more information on the company please contact Mr. Luc Cournoyer at 514-596-2901.
SOURCE: LAUREATE PHARMA, INC.